2003
DOI: 10.1038/nm0703-874
|View full text |Cite
|
Sign up to set email alerts
|

HIV vaccines 1983–2003

Abstract: Twenty years after the discovery of HIV, there is still no vaccine. This year, an envelope vaccine aimed at stimulating neutralizing antibodies was unable to protect against infection in phase 3 trials. But more than 20 HIV vaccines designed to stimulate T-cell responses are being developed. Will any of them work?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
146
0
2

Year Published

2004
2004
2010
2010

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 223 publications
(149 citation statements)
references
References 109 publications
1
146
0
2
Order By: Relevance
“…Neutralizing antibodies, the correlate of vaccine-induced protection against most viral infections, that broadly cross-neutralize HIV-1 isolates, cannot currently be induced by vaccines. 26,27 It is assumed based on preclinical studies with SIV that HIV-1 specific T cells will not provide sterilizing immunity or allow for complete clearance of HIV-1 but rather lower the set point viral load and thus reduce morbidity and further spread of the virus. As HIV-1 rapidly mutates in infected hosts, the vaccine-induced CD8 + T-cell response has to be of sufficient breadth to prevent outgrowth of escape mutants.…”
Section: Discussionmentioning
confidence: 99%
“…Neutralizing antibodies, the correlate of vaccine-induced protection against most viral infections, that broadly cross-neutralize HIV-1 isolates, cannot currently be induced by vaccines. 26,27 It is assumed based on preclinical studies with SIV that HIV-1 specific T cells will not provide sterilizing immunity or allow for complete clearance of HIV-1 but rather lower the set point viral load and thus reduce morbidity and further spread of the virus. As HIV-1 rapidly mutates in infected hosts, the vaccine-induced CD8 + T-cell response has to be of sufficient breadth to prevent outgrowth of escape mutants.…”
Section: Discussionmentioning
confidence: 99%
“…Most, if any, of the current vaccines target the development of an effective long-lasting virus-specific CD8 þ T-cell response. 4 The possibility, however, that the vaccine-induced CD8 þ T cells will also be sensitive to apoptosis cannot be excluded. This possibility is even higher in the case of therapeutic vaccines where HIV infection has established already an environment that favors the apoptosis of CTLs.…”
Section: Discussionmentioning
confidence: 99%
“…An ideal HIV vaccine should be able to elicit a robust long-lasting immunity, capable of controlling a wide variety of HIV isolates. 4 Thus, reconstitution and reinforcement of the CTL function against multiple HIV epitopes is a major goal of therapeutic strategies and vaccines against HIV. Understanding and overcoming the apoptotic defect of naturally occurring and vaccine-elicited HIV-specific CD8 þ T cells therefore is an important goal in the quest for novel cellular immunity-based therapies, and therapeutic and preventive vaccines.…”
mentioning
confidence: 99%
“…Such vaccines offer promising approaches to some of the most intractable problems in human health, such as malaria (25), HIV (26), and cancer (27). However, there are few tools available that allow T-cell responses to be evaluated with the consistency necessary to meet regulatory standards for vaccine trials.…”
Section: Original Articlesmentioning
confidence: 99%